Amicus Therapeutics (NASDAQ:FOLD) Shares Pass Above Two Hundred Day Moving Average - What's Next?

Key Points

• Amicus Therapeutics' stock price surpassed its 200-day moving average, indicating a potential shift in market momentum, trading as high as $8.43 with a last recorded price of $8.16.
• Recent analyst ratings have been mixed, with eight analysts giving a Buy rating, one a Hold, and one a Sell, while the consensus price target stands at $15.78.
• Institutional interest has increased, with several hedge funds significantly raising their stakes in Amicus Therapeutics during the first quarter, including GAMMA Investing LLC increasing its holdings by 1,610.8%.

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.89 and traded as high as $8.43. Amicus Therapeutics shares last traded at $8.16, with a volume of 4,235,173 shares.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on FOLD shares. Wall Street Zen upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, September 20th. Weiss Ratings reissued a "sell (e+)" rating on shares of Amicus Therapeutics in a report on Saturday, September 27th. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Finally, Needham & Company LLC raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 target price on the stock in a research report on Thursday, September 18th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.78.

Amicus Therapeutics Trading Down 0.5%

The business's 50-day moving average price is $7.58 and its 200-day moving average price is $6.89. The firm has a market capitalization of $2.52 billion, a PE ratio of -67.99 and a beta of 0.56. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29.

Institutional Trading of Amicus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in FOLD. GAMMA Investing LLC lifted its stake in shares of Amicus Therapeutics by 1,610.8% in the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 7,007 shares during the period. Rhumbline Advisers raised its holdings in Amicus Therapeutics by 6.9% during the first quarter. Rhumbline Advisers now owns 440,351 shares of the biopharmaceutical company's stock worth $3,593,000 after purchasing an additional 28,383 shares in the last quarter. Procyon Advisors LLC lifted its position in Amicus Therapeutics by 74.5% in the first quarter. Procyon Advisors LLC now owns 42,576 shares of the biopharmaceutical company's stock valued at $347,000 after purchasing an additional 18,184 shares during the period. SG Americas Securities LLC boosted its holdings in Amicus Therapeutics by 137.6% in the 1st quarter. SG Americas Securities LLC now owns 100,993 shares of the biopharmaceutical company's stock valued at $824,000 after purchasing an additional 58,496 shares in the last quarter. Finally, Diversified Trust Co boosted its holdings in Amicus Therapeutics by 2.2% in the 1st quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company's stock valued at $682,000 after purchasing an additional 1,784 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.